OPRX

$6.69+0.16 (+2.45%)

Market OpenAs of Mar 17, 7:06 PM UTC

OptimizeRx Corporation operates as a digital healthcare technology company.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$6.69
Potential Downside
24%
Whystock Fair Value$5.09
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryHealth Information Services

OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, wh...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$125.50M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.78
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
4.18%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.91

Recent News

Zacks
Mar 16, 2026

Is OptimizeRx (OPRX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

Best Value Stocks to Buy for March 16th

OPRX, NVST and STRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 16, 2026.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Mar 6, 2026

OptimizeRx Corporation Q4 2025 Earnings Call Summary

Moby summary of OptimizeRx Corporation's Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
GuruFocus.com
Mar 6, 2026

OptimizeRx Corp (OPRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

OptimizeRx Corp (OPRX) reports robust Q4 performance with $32.2 million in revenue, while navigating market shifts and setting conservative 2026 guidance.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 6, 2026

OptimizeRx Q4 Earnings Call Highlights

OptimizeRx (NASDAQ:OPRX) reported fourth-quarter and full-year fiscal 2025 results that management said exceeded both internal expectations and consensus estimates, driven by growth across established customers and a rising contribution from mid-tier and “long-tail” life sciences companies. The comp

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.